Table 1 (abstract A9). Study characteristics
Study | N | Study design | Intake protocols | Outcome |
|---|---|---|---|---|
Ostojic et al. [2] | 36 | RT, SB | 4 tablets x 3 oral (2g per day) 6 times per day for 20 min topical 14 days | Plasma viscosity ↓ (ROM) recovery ↑ CRP → Interleukin 6 → Pain scores → |
Drid et al. [4] | 8 | RT, DB, PC, CO | 300 mL of HRW 30 min before exercise 4 days | pH ↑ Bicarbonate (mmol/L) ↔ Lactate (mmol/L) ↓ Heart rate (beats per min) ↔ |
Aoki et al. [5] | 10 | RT, DB, PC, CO | 500mL × 3 before exercise 7 days | d-ROMs, → BAP → CK → Lactate ↓ Peak torque ↑ |
Ponte et al. [6] | 8 | RT, PC, SB, CO | 2 L per day (pH9.8, free hydrogen content 450 ppb) 14 days | PPO ↑ pH → Lactate → HCO3 → |
Mikami et al. [7] | 159 | RT, DB, PC | 500mL 0,8mh/L (0,8ppm) 1,0 mg/L (1.0ppm) | VO2max ↑ VAS ↓ |
Javorac et al. [3] | 20 | RT, DB, PC, CO | 20 min inhalation 7 days | CRP ↓ FER ↓ ESR → IGF-1 ↓ MVIS ↑ MRS ↑ VO2max → |